UBS downgraded Novo Nordisk to “neutral” from “buy” and slashed its 12-month price target to 340 Danish kroner from 600 kroner, warning that unregulated compounded versions of semaglutide and intensifying competition from Eli Lilly’s Mounjaro will erode growth for Wegovy and Ozempic. The Swiss bank expects U.S. sales of Novo’s GLP-1 drugs to rise only 6 % in the second half, well below previous assumptions. The downgrade landed hours after investors filed a class-action lawsuit in the United States accusing the Danish drugmaker of overstating demand projections for semaglutide-based medicines and downplaying competitive threats between May and July. Plaintiffs say the company’s optimistic guidance and subsequent share slide caused significant losses. Novo Nordisk’s troubles follow last week’s profit warning, in which it cut its 2025 sales growth outlook to 8–14 % from 13–21 %. The alert prompted Nykredit to lower its economic forecast for Denmark, underscoring the weight the country’s largest company carries for domestic growth.
Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason. https://t.co/yLFz2CGAJ1
Novo Nordisk, the maker of the weight-loss drug Wegovy was sued in US court by investors claiming it misled them with optimistic growth forecasts and minimized competition risks in the obesity market. Subscribe to The Daily Docket: https://t.co/s1z0JFig0G https://t.co/ALudyPTr6W
🔴A Novo Nordisk le crecen los problemas: Demanda colectiva y rebaja de UBS La farmacéutica danesa sufre presiones regulatorias y legales en EE.UU. mientras le recortan su calificación y expectativas de crecimiento. https://t.co/rTyGvQIwU0